Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting (Q33959120)

30 July 2017

1 reference

title

Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting (English)

1 reference

30 July 2017

1 reference

1 reference

K Simpson

1

1 reference

30 July 2017

C M Spencer

series ordinal

2

1 reference

30 July 2017

K J McClellan

series ordinal

3

1 reference

30 July 2017

1 June 2000

1 reference

30 July 2017

1 reference

30 July 2017

59

1 reference

30 July 2017

6

1 reference

30 July 2017

1297-1315

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200059060-00008

30 July 2017

0 references

cites work

Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy

1 reference

12 December 2020

Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting--the Nordic experience.

1 reference

12 December 2020

The development of tropisetron in its clinical perspective

1 reference

12 December 2020

Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis

1 reference

12 December 2020

Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone

1 reference

12 December 2020

Tropisetron in the prevention of acute and delayed nausea and vomiting over six courses of emetogenic chemotherapy

1 reference

12 December 2020

Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting

1 reference

12 December 2020

5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—A randomised study

1 reference

12 December 2020

Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone

1 reference

12 December 2020

Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic

1 reference

12 December 2020

A randomized, double-blind, multicentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy

1 reference

12 December 2020

Tropisetron in the prevention of chemotherapy-induced nausea and vomiting in patients responding poorly to previous conventional antiemetic therapy

1 reference

12 December 2020

Tropisetron. A review of the clinical experience

1 reference

12 December 2020

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

1 reference

12 December 2020

Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study

1 reference

12 December 2020

[A randomized trial of tropisetron in the prophylaxis of nausea and vomiting induced by chemotherapy]

1 reference

12 December 2020

5-HT3 receptor antagonists: differences and similarities

1 reference

12 December 2020

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.

1 reference

12 December 2020

Tropisetron alone or in combination with dexamethasone for the prevention and treatment of emesis induced by non-cisplatin chemotherapy

1 reference

12 December 2020

Efficacy of tropisetron (Navoban) in controlling emesis induced in children by anti-cancer therapy

1 reference

12 December 2020

Clinical phase II study of tropisetron capsule in the treatment of nausea and vomiting induced by anti-cancer drugs

1 reference

12 December 2020

Optimal combination therapy with Navoban (tropisetron) in patients with incomplete control of chemotherapy-induced nausea and vomiting. The Belgian Navoban Group.

1 reference

12 December 2020

Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group

1 reference

12 December 2020

Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained

1 reference

12 December 2020

Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.

1 reference

12 December 2020

Tropisetron in the control of nausea and vomiting induced by combined cancer chemotherapy in children.

1 reference

12 December 2020

A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis

1 reference

12 December 2020

Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group

1 reference

12 December 2020

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Em

1 reference

12 December 2020

Control of nausea and vomiting by Navoban (tropisetron) in 131 children receiving cytotoxic chemotherapy.

1 reference

12 December 2020

Extrapyramidal reactions with metoclopramide

1 reference

12 December 2020

A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis

1 reference

12 December 2020

Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. The Nordic Antiemetic Trial Group.

1 reference

12 December 2020

Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis

1 reference

12 December 2020

Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies.

1 reference

12 December 2020

Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis

1 reference

12 December 2020

Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.

1 reference

12 December 2020

The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy: a randomized crossover trial

1 reference

12 December 2020

Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.

1 reference

12 December 2020

Granisetron plus dexamethasone in moderately emetogenic chemotherapy: evaluation of activity during three consecutive courses of chemotherapy

1 reference

12 December 2020

Pharmacokinetics of the 5HT3 receptor antagonist tropisetron in children.

1 reference

12 December 2020

Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting

1 reference

12 December 2020

Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results

1 reference

12 December 2020

A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis

1 reference

12 December 2020

Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea.

1 reference

12 December 2020

1 reference

12 December 2020

Ondansetron and Tropisetron with Dexamethasone in the Prophylaxis of Acute Vomiting Induced by Non-cisplatin-Containing Chemotherapy

1 reference

12 December 2020

Tropisetron (ICS 205-930) in pediatric oncology: first results in patients refractory to antiemetic metoclopramide-based treatments

1 reference

12 December 2020

Guidelines for anti-emetic therapy: acute emesis

1 reference

12 December 2020

Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms

1 reference

12 December 2020

Prevention of emesis by tropisetron in children receiving combined chemotherapy with cisplatin

1 reference

12 December 2020

Efficacy and tolerability of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin

1 reference

12 December 2020

A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis

1 reference

12 December 2020

Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer

1 reference

12 December 2020

Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans

1 reference

12 December 2020

Antiemetic efficacy of tropisetron in patients failing previous antiemetic therapy

1 reference

12 December 2020

Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine

1 reference

12 December 2020

Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC)

1 reference

12 December 2020

[Tropisetron versus ondansetron in the prevention and control of emesis in patients undergoing chemotherapy with FAC/FEC for metastatic or surgically treated breast carcinoma].

1 reference

12 December 2020

Effects of anti-emetic drug (tropisetron) on quality of life during chemotherapy: use of a diary-type questionnaire and application of summary measures for assessment in a randomized, multicentre study. Joint Research Group for Tropisetron Double-Bl

1 reference

12 December 2020

10.2165/00003495-200059060-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference